Health authorities introduced the estimand framework to improve clinical trial reporting and design. This methodology addresses significant ambiguities, such as non-adherence and "intention-to-treat" definitions. While the framework originally grounded its principles in individually randomised trials, its application to cluster randomised trials (CRTs) presents unique challenges. Specifically, researchers must navigate "informative cluster size," where the cluster's scale may modify the treatment effect. Consequently, the interpretation of results requires a more nuanced approach than standard trial designs.

Implementing the Estimand Framework in Cluster Trials

Stakeholders often view trial objectives through different lenses. For example, a politician or population-level decision maker typically seeks the overall impact on a community. Conversely, a cluster manager focuses on the performance of their specific unit. Individual patients primarily care about the expected outcome for someone like them. Because these perspectives differ, the target estimand must align with the intended stakeholder's needs. Therefore, trialists should define these goals clearly during the design phase to avoid misleading conclusions.

Researchers should also resist the urge to abandon sophisticated statistical modeling in favor of simpler averages. In the presence of informative cluster size, modeling the interaction between size and treatment remains vital. This approach provides a clearer picture for various decision-makers across the healthcare spectrum. Furthermore, careful modeling ensures that the trial remains robust against potential biases. Ultimately, the estimand framework serves as a "golden thread" linking trial objectives directly to the statistical analysis.

Frequently Asked Questions

What is informative cluster size in clinical trials?

Informative cluster size refers to the phenomenon where the treatment effect or participant outcomes vary based on the number of individuals in a cluster. This situation complicates analysis because weighting by individual or by cluster can produce different statistical results.

Why is the estimand framework important for CRTs?

The framework forces researchers to define exactly what they intend to estimate before the study begins. By addressing intercurrent events and diverse stakeholder perspectives early, it ensures that the statistical analysis answers the specific clinical or regulatory question intended.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. It is not a substitute for professional medical expertise. Refer to the latest local and national guidelines for clinical practice.

References

Hooper R et al. The wood and the trees: estimands in cluster randomised trials. Trials. 2026 Apr 20. doi: undefined. PMID: 42010658.

ICH E9(R1) Addendum on Estimands and Sensitivity Analysis in Clinical Trials. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). 2019.

Hemming K, Taljaard M. Estimands in cluster trials: thinking carefully about the target of inference and the consequences for analysis choice. International Journal of Epidemiology. 2022;51(6):1741-1743. doi: 10.1093/ije/dyac174.